Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NanoDisk
- Development stage
- Unknown
- Lead developer
- Children's Hospital Oakland Research Institute
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
NanoDisk is a biomimetic nanoparticle drug delivery platform consisting of a discoidal phospholipid bilayer stabilized by amphipathic scaffold proteins, most commonly apolipoprotein A-I (ApoA-I). Developed by NanoDisk, Inc. in collaboration with the Children's Hospital Oakland Research Institute (CHORI), the technology is designed to solubilize and transport hydrophobic or membrane-active therapeutic agents. By mimicking the structure and function of endogenous high-density lipoproteins (HDL), NanoDisks facilitate targeted delivery to tissues expressing scavenger receptors, such as SR-BI, while significantly reducing the systemic toxicity associated with traditional lipid-based formulations. The platform's lead candidate, NanoDisk-Amphotericin B (ND-AMB), has been investigated for the treatment of systemic fungal infections, including coccidioidomycosis, demonstrating a superior safety profile and reduced nephrotoxicity compared to conventional amphotericin B deoxycholate.
- Brand names
- NanoDisk
- Other names
- NanoDisk-Amphotericin BND-AmBNanoDisk-ApoA-I
02
Targets
SCARB1 (Scavenger receptor class B member 1)
Beyond the preview
Go deeper on NanoDisk.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoDisk.